ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

solriamfetol

Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.

Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.

Drug pageSolriamfetol: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 25, 202122 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Axsome Therapeutics117 open or runningphase 4since Feb 25, 2021Feb 25, 2021Dec 2026phase 3 · NCT06413433
Jazz Pharmaceuticalsits history only90 open or runningphase 3since Jan 15, 2015Dec 2, 2011none ahead
Ignis Therapeutics (Suzhou)its history only10 open or runningphase 3since Sep 27, 2023Sep 27, 2023none ahead
Johnson & Johnsonits history only10 open or runningphase 2since Nov 17, 2003Nov 17, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Axsome Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named solriamfetolINNProposed as its International Nonproprietary Name in WHO's List 116 · before, JZP-110
  2. Feb 25, 2021First study: phase 4 study in Disorders of Excessive SomnolenceFirst studyNCT04789174 · 59 enrolled · United States, Canada, Italy and more
  3. Aug 10, 2021Phase 1 study in NarcolepsyNCT05008341 · 6 enrolled · United States
  4. Jul 25, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05972044 · 516 enrolled · United States
  5. Apr 8, 2024Phase 3 study in Depressive Disorder, MajorNCT06360419 · 346 enrolled · United States
  6. May 9, 2024Phase 3 study in Binge-Eating DisorderNCT06413433 · 450 planned · United States
  7. Aug 21, 2024Phase 3 study in Disorders of Excessive SomnolenceNCT06568367 · 520 planned · United States, Canada
  8. Mar 14, 2025Phase 3 study in Binge-Eating DisorderNCT06878976 · 236 planned · United States
  9. Mar 16, 2026Phase 3 study in Depressive Disorder, MajorNCT07484217 · 508 planned · United States
  10. Jul 16, 20262 phase 3 studies in Attention Deficit Disorder with HyperactivityNCT07717892, NCT07717879
  11. Aug 14, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityNCT07773883 · 300 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Disorders of Excessive SomnolenceNCT06568367
  2. Dec 2026Primary completion: phase 3 study in Binge-Eating DisorderNCT06413433
  3. Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07773883
  4. Dec 2027Primary completion: phase 3 study in Binge-Eating DisorderNCT06878976

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 Axsome Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07773883Attention Deficit Disorder with Hyperactivity · United States3By invitationDec 2027300
NCT07717892Attention Deficit Disorder with Hyperactivity · United States3RecruitingJun 30, 2028468
NCT07717879Attention Deficit Disorder with Hyperactivity · United States3RecruitingJun 30, 2028468
NCT07484217Depressive Disorder, Major · United States3RecruitingDec 2028508
NCT06878976Binge-Eating Disorder · United States3By invitationDec 2027236
NCT06568367Disorders of Excessive Somnolence · United States, Canada3RecruitingDec 2026520
NCT06413433Binge-Eating Disorder · United States3RecruitingDec 2026450
NCT06360419Depressive Disorder, Major · United States3CompletedDec 31, 2024346
NCT05972044Attention Deficit Disorder with Hyperactivity · United States3CompletedFeb 7, 2025516
NCT05008341Narcolepsy · United States1CompletedApr 15, 20226
NCT04789174Disorders of Excessive Somnolence · United States, Canada, Italy and more4CompletedSep 19, 202259

How it is read

Names in the registry

  • “JZP-110”, 7 entries
  • “Solriamfetol”, 4 entries
  • “Solriamfetol 300 mg”, 4 entries
  • “Solriamfetol 150 mg”, 3 entries
  • “Solriamfetol Dose A”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.